MeiraGTx Signs J&J To Develop Gene Therapies For Rare Retinal Diseases
Executive Summary
While it wants to keep other programs for diseases with larger patient populations in house, MeiraGTx believes J&J offers the global reach to expedite its program in inherited retinal diseases, including three clinical candidates.
You may also be interested in...
Deal Watch: Novartis Partners In CNS Gene Therapies A Second Time With Voyager
Plus deals involving AstraZeneca/Allorion, Concentra/Theseus, Janssen/MeiraGTx, Lilly/Fauna and more.
Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
Where Is J&J Investing For The Future? Cell Therapy, Gene Therapy And RNA
Janssen global head of R&D Mathai Mammen said the three areas are therapeutic modalities J&J is prioritizing for future drug development, both internally and through partnering.